MRD assessment in a diverse population of patients with early-stage breast cancer -DCT

This research study seeks to improve the treatment of early-stage breast cancer by examining circulating tumor DNA (ctDNA). CtDNA, a biomarker found in the blood, may indicate the presence of residual disease after initial treatment. The study aims to determine if ctDNA analysis can help doctors personalize adjuvant therapies, such as radiation and systemic therapy, leading to more effective treatment plans. A significant focus is placed on including African American/Black patients, a population often underrepresented in genomic research. By analyzing ctDNA in this group, researchers hope to gain valuable insights into the disease's characteristics and improve treatment outcomes, ultimately reducing disparities in breast cancer care. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.